I-MAB (IMAB) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
I-Mab, a U.S.-based global biotech firm focusing on cancer immunotherapies, has appointed PricewaterhouseCoopers LLP as its independent auditor for fiscal year 2024. This move is part of I-Mab’s strategic shift to reinforce its presence as a U.S. biotech entity, with no reported issues from the previous auditor. The company leaders express confidence in PwC’s alignment with shareholder interests and the firm’s capabilities to support I-Mab’s long-term growth objectives.
For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.
